NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia · Delayed Price · Currency is AUD | Market Cap | 25.33M -53.8% |
| Revenue (ttm) | 402.66K |
| Net Income | -4.69M |
| EPS | -0.01 |
| Shares Out | 389.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,914 |
| Open | 0.0660 |
| Previous Close | 0.0650 |
| Day's Range | 0.0610 - 0.0660 |
| 52-Week Range | 0.0550 - 0.1800 |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 1, 2026 |
About ASX:NSB
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia. [Read more]
Financial Performance
Financial StatementsNews
NeuroScientific Biopharmaceuticals Annual report: H2 2026
NeuroScientific Biopharmaceuticals has published its H2 2026 annual report on August 24, 2026.
NeuroScientific Biopharmaceuticals Earnings release: Q4 2026
NeuroScientific Biopharmaceuticals released its Q4 2026 earnings on July 27, 2026, summarizing the period's financial results.
NeuroScientific Biopharmaceuticals Ltd Investor Webinar Transcript
NeuroScientific Biopharmaceuticals Ltd Investor Webinar Transcript
NeuroScientific Biopharmaceuticals Transcript: Status update
Four out of five patients with fistulizing Crohn's disease showed strong clinical response to StemSmart in a Special Access Program, prompting two phase II trials to launch by year-end. The therapy is safe, systemically administered, and targets a major unmet need in Crohn's, with global commercialization and regulatory milestones underway.
NeuroScientific Biopharmaceuticals Earnings release: Q3 2026
NeuroScientific Biopharmaceuticals released its Q3 2026 earnings on June 15, 2026, summarizing the period's financial results.
NeuroScientific Biopharmaceuticals Slides: Investor presentation
NeuroScientific Biopharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 25, 2026.
NeuroScientific Biopharmaceuticals Quarterly report: H1 2026
NeuroScientific Biopharmaceuticals has published its H1 2026 quarterly earnings report on February 24, 2026.
NeuroScientific Biopharmaceuticals Slides: Company presentation
NeuroScientific Biopharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on February 15, 2026.
NeuroScientific Biopharmaceuticals Transcript: Investor Update
A new stem cell platform was acquired, shifting focus to Crohn's disease and other high-value indications. Early clinical data is strong, with a special access program underway and phase two trials planned. Manufacturing and advisory partnerships de-risk development and support future expansion.
NeuroScientific Biopharmaceuticals Earnings release: Q1 2026
NeuroScientific Biopharmaceuticals released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
NeuroScientific Biopharmaceuticals Slides: Investor Presentation
NeuroScientific Biopharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2025.